🔎 Trials Near Me

Home › Epilepsy › Illinois

Pag-aaral pangklinika para sa Epilepsy sa Illinois

7 pag-aaral para sa Epilepsy ang naghahanap ng mga kalahok sa mga site sa Illinois.

Mga Lungsod sa Illinois

Opisyal na teksto ng pag-aaral (English)

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

  • Southern Illinois University Neurology Clinic, Springfield
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07563881

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

  • Re:Cognition Health-Chicago, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07594119

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  • Southern Illinois University School of Medicine, Springfield
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT05667142

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

  • Southern Illinois University School of Medicine, Springfield
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT05716100

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

  • Rush University Medical Center, Chicago
  • University of Chicago, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT05135091

Artificial Intelligence for Brain MRI Analysis in Epilepsy

  • Rush Hospital, Chicago
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT07881185

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

  • Praxis Research Site, Chicago
Nagre-recruitPhase 3
1 Day – 18 Years · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT07019922

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.